Paper6772097
Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds.
Wise R and 2 others. Antimicrob Agents Chemother, 1980. Cited by 112 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Papers, record 6772097. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6772097
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacteria | Major topic |
| Cephalosporins | Major topic |
| Anti-Bacterial Agents | |
| Bacteroides fragilis | |
| Ceftazidime | |
| Enterobacteriaceae | |
| Microbial Sensitivity Tests | |
| Pseudomonas aeruginosa |
Source PubMed
References6
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 101,128 | beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin. | Antimicrob Agents Chemother | 1978 | https://conductscience.org/library/papers/101128 | PubMed |
| 2 | 253,572 | HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin. | Antimicrob Agents Chemother | 1978 | https://conductscience.org/library/papers/253572 | PubMed |
| 3 | 314,774 | Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds. | Antimicrob Agents Chemother | 1979 | https://conductscience.org/library/papers/314774 | PubMed |
| 4 | 507,788 | LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics. | Antimicrob Agents Chemother | 1979 | https://conductscience.org/library/papers/507788 | PubMed |
| 5 | 6,994,642 | GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. | Antimicrob Agents Chemother | 1980 | https://conductscience.org/library/papers/6994642 | PubMed |
| 6 | 4,208,895 | Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. | Antimicrob Agents Chemother | 1972 | https://conductscience.org/library/papers/4208895 | PubMed |
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 112 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 35,401,470 | The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition. | Front Microbiol | 2022 | https://conductscience.org/library/papers/35401470 | PubMed |
| 29,110,143 | Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review. | Infection | 2018 | https://conductscience.org/library/papers/29110143 | PubMed |
| 10,390,248 | Altered pharmacokinetics of ceftazidime in critically ill patients. | Antimicrob Agents Chemother | 1999 | https://conductscience.org/library/papers/10390248 | PubMed |
| 9,021,183 | In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/9021183 | PubMed |
| 8,239,592 | Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8239592 | PubMed |
| 7,030,200 | Comparison of ceftazidime and cefamandole pharmacokinetics and blister fluid concentrations. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/7030200 | PubMed |
| 7,023,381 | Activity of ceftazidime (GR 20263) against nosocomially important pathogens. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/7023381 | PubMed |
| 6,972,728 | Comparison of in vitro activities of eight beta-lactamase-stable cephalosporins against beta-lactamase-producing gram-negative bacilli. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/6972728 | PubMed |
| 6,818,153 | [N-formimidoyl-thienamycin: in vitro activity in bacteria with resistance to beta-lactam antibiotics or gentamicin]. | Infection | 1982 | https://conductscience.org/library/papers/6818153 | PubMed |
| 6,436,021 | In vitro activity of ciprofloxacin, azthreonam and ceftazidime against Serratia marcescens and Pseudomonas aeruginosa. | Eur J Clin Microbiol | 1984 | https://conductscience.org/library/papers/6436021 | PubMed |
| 6,357,068 | Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6357068 | PubMed |
| 6,354,685 | Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. | Drugs | 1983 | https://conductscience.org/library/papers/6354685 | PubMed |
| 6,339,418 | Therapeutic and kinetic properties of ceftazidime in animals. | Infection | 1983 | https://conductscience.org/library/papers/6339418 | PubMed |
| 6,339,416 | Criteria for the assessment of susceptibility to ceftazidime using the disc diffusion procedure. | Infection | 1983 | https://conductscience.org/library/papers/6339416 | PubMed |
| 6,303,743 | Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use. | Drugs | 1983 | https://conductscience.org/library/papers/6303743 | PubMed |
| 6,299,967 | The in vitro activity of ceftazidime against resistant clinical isolates. | Infection | 1983 | https://conductscience.org/library/papers/6299967 | PubMed |
| 6,297,384 | Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats. | Antimicrob Agents Chemother | 1982 | https://conductscience.org/library/papers/6297384 | PubMed |
| 6,275,776 | Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/6275776 | PubMed |
| 3,890,729 | In vitro studies on the antibacterial activities of YM-13115, a new broad-spectrum cephalosporin. | Antimicrob Agents Chemother | 1985 | https://conductscience.org/library/papers/3890729 | PubMed |
| 3,884,319 | Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. | Drugs | 1985 | https://conductscience.org/library/papers/3884319 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6772097
GET https://conductscience.org/api/papers/v1/6772097/cited_by?page=2